Ingalls & Snyder LLC Biomarin Pharmaceutical Inc Transaction History

Ingalls & Snyder LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 27, 2021	SELL	$74.77 - $85.47 $551,802 - $630,768	-7,380 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$75.51 - $84.79 $131,009 - $147,110	-1,735 Reduced 19.03%	7,380 $616,000
Q1 2021 Apr 21, 2021	SELL	$74.73 - $90.69 $116,578 - $141,476	-1,560 Reduced 14.61%	9,115 $688,000
Q4 2020 Jan 27, 2021	SELL	$72.61 - $90.2 $11,980 - $14,883	-165 Reduced 1.52%	10,675 $936,000
Q3 2020 Oct 21, 2020	BUY	$71.87 - $131.03 $779,070 - $1.42 Million	10,840 New	10,840 $825,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.